Shares of Oxford Immunotec Global PLC (NASDAQ:OXFD) were down 0.2% during mid-day trading on Friday . The company traded as low as $8.76 and last traded at $8.81, with a volume of 66,515 shares traded. The stock had previously closed at $8.83.

A number of analysts recently issued reports on OXFD shares. Piper Jaffray Cos. restated a “buy” rating on shares of Oxford Immunotec Global PLC in a report on Sunday, June 26th. BTIG Research restated a “buy” rating and set a $17.00 price objective on shares of Oxford Immunotec Global PLC in a report on Monday, June 27th. Finally, Zacks Investment Research downgraded shares of Oxford Immunotec Global PLC from a “buy” rating to a “hold” rating in a report on Wednesday.

The stock has a 50 day moving average price of $9.00 and a 200-day moving average price of $10.07. The company’s market capitalization is $198.81 million.

Oxford Immunotec Global PLC (NASDAQ:OXFD) last announced its earnings results on Tuesday, May 3rd. The company reported ($0.32) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.32). The business had revenue of $17.10 million for the quarter, compared to the consensus estimate of $16.96 million. During the same quarter last year, the firm posted ($0.31) EPS. The business’s quarterly revenue was up 23.9% on a year-over-year basis. Analysts forecast that Oxford Immunotec Global PLC will post ($1.25) EPS for the current fiscal year.

An institutional investor recently raised its position in Oxford Immunotec Global PLC stock. OppenheimerFunds Inc. raised its position in shares of Oxford Immunotec Global PLC (NASDAQ:OXFD) by 0.5% during the fourth quarter, according to its most recent filing with the SEC. The fund owned 1,068,967 shares of the company’s stock after buying an additional 5,440 shares during the period. OppenheimerFunds Inc. owned about 4.74% of Oxford Immunotec Global PLC worth $12,293,000 at the end of the most recent quarter.

Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company focused on developing and commercializing tests for the management of immune-regulated conditions. The Company’s T-SPOT technology platform allows it to measure the responses of specific immune cells to inform the diagnosis, prognosis and monitoring of patients with immune-regulated conditions.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.